Drugs / Ormutivimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02559921 | Dec 2014 → Aug 2015 | rabies | Beijing Chaoyang District Centre for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ormutivimab | “Ormutivimab is the first recombinant human anti-rabies monoclonal antibody (rhRIG) approved for clinical application in China.” PMID 36016106 ↗ Jul 2022 |
| Known as | rhRIG | “Ormutivimab is the first recombinant human anti-rabies monoclonal antibody (rhRIG) approved for clinical application in China.” PMID 36016106 ↗ Jul 2022 |
| Modality | Monoclonal antibody | “Ormutivimab is the first recombinant human anti-rabies monoclonal antibody (rhRIG) approved for clinical application in China.” PMID 36016106 ↗ Jul 2022 |